论文部分内容阅读
用放射免疫法分别测定前列腺癌（18例）、前列腺增生（60例）和慢性前列腺炎（60例）患者以及健康男性（40例）的血清前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）含量,并随访观察10例前列腺癌接受内分泌治疗后PSA与PAP的变化。结果表明,二者含量在前列腺癌组与其它各组间存在非常显著性差异（P<0.01）;PSA诊断前列腺癌的敏感性（88.9％）明显高于PAP（50％）,P<0.05;但特异性均不高。提示二者作为早期前列腺癌的筛选诊断指标有一定局限性,但在监测疗效和病情变化方面,因两者浓度高低与病情一致而具有实用价值,且PSA较PAP灵敏。因此认为,PSA可完全取代PAP作为目前临床前列腺癌的肿瘤标记物。
Serum prostate-specific antigen (PSA) and prostatic acid phosphatase (PSA) in prostate cancer (18 cases), benign prostatic hyperplasia (60 cases) and chronic prostatitis (60 cases) and healthy men (40 cases) were measured by radioimmunoassay. PAP) content, and follow-up observed 10 cases of prostate cancer after receiving endocrine therapy changes in PSA and PAP. The results showed that there was a significant difference between the prostate cancer group and other groups (P<0.01). The sensitivity of PSA in the diagnosis of prostate cancer (88.9%) was significantly higher than that of PAP (50%), P<0.05; However, the specificity is not high. It is suggested that both have some limitations as screening diagnostic indicators for early prostate cancer, but in terms of monitoring efficacy and changes in disease status, both the concentration level and the disease condition have practical value, and PSA is more sensitive than PAP. Therefore, it is believed that PSA can completely replace PAP as a tumor marker for clinical prostate cancer.